ARK Investment Management LLC Has $47.36 Million Stake in Adaptive Biotechnologies Corporation $ADPT

ARK Investment Management LLC trimmed its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 21.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,165,636 shares of the company’s stock after selling 850,849 shares during the period. ARK Investment Management LLC owned approximately 2.07% of Adaptive Biotechnologies worth $47,358,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ADPT. First Trust Advisors LP raised its stake in shares of Adaptive Biotechnologies by 4,802.2% in the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after purchasing an additional 726,184 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in Adaptive Biotechnologies in the 2nd quarter valued at $6,618,000. Cubist Systematic Strategies LLC acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at $5,346,000. Geode Capital Management LLC raised its stake in shares of Adaptive Biotechnologies by 15.6% in the 2nd quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after buying an additional 434,347 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 255.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 589,611 shares of the company’s stock worth $6,869,000 after acquiring an additional 423,780 shares during the period. Institutional investors own 99.17% of the company’s stock.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Company reported a quarterly earnings beat with strong revenue growth (revenue up ~51% YoY), which underpins the stock’s positive momentum. MarketBeat ADPT summary
• Positive Sentiment: Several sell-side firms raised price targets or reiterated Buy/Overweight ratings (Guggenheim, JPMorgan, Piper Sandler, Wall Street Zen), giving investors analyst support for higher valuations. Analyst coverage summary
• Neutral Sentiment: Reported short-interest entries show 0 shares (days-to-cover 0.0) — this appears to be a data error or non-material and shouldn’t be interpreted as meaningful short activity. (No actionable link.)
• Neutral Sentiment: Small institutional activity: several funds reported modest new or increased positions in the fourth quarter; institutional ownership remains high (~99%), so movements are incremental. MarketBeat ownership note
• Negative Sentiment: CEO Chad Robins executed multiple large sales in late Feb–early Mar (including 53,083 shares on Mar 3 and larger blocks on Mar 2 and Feb 27), reducing his stake materially; large insider sales can create short-term selling pressure or raise governance/insider-confidence questions. Chad Robins sale alert
• Negative Sentiment: Director/insider Harlan S. Robins also sold smaller blocks (10,000 and 14,233 shares on Mar 2–3), further increasing headline insider selling volume. Harlan S. Robins filings

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ADPT. JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Guggenheim increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 34,668 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.60, for a total transaction of $644,824.80. Following the sale, the insider owned 1,187,644 shares of the company’s stock, valued at $22,090,178.40. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Hershberg sold 22,968 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $16.00, for a total transaction of $367,488.00. Following the completion of the sale, the director owned 46,722 shares of the company’s stock, valued at $747,552. The trade was a 32.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,082,417 shares of company stock worth $17,725,999 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $16.44 on Thursday. The company has a market capitalization of $2.53 billion, a P/E ratio of -41.10 and a beta of 2.19. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76. The business’s 50 day simple moving average is $16.85 and its 200-day simple moving average is $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.23) EPS. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.